[A24-43] vacaftor/tezacaftor/elexacaftor (combination with ivacaftor; cystic fibrosis, 2 to 5 years, F508del mutation, MF mutation, heterozygous) - Addendum to Project A23-122
Last updated 16.05.2024
Project no.:
A24-43
Commission:
Commission awarded on 15.04.2024 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Digestion, metabolism and hormones
Patients with cystic fibrosis from 2 to 5 years of age who are heterozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator gene and have a minimal function mutation on the second allele
Unchanged after addendum:
added benefit not proven
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
https://doi.org/10.60584/A24-43_en
| Project no. | Title | Status |
|---|---|---|
| A23-122 | Ivacaftor/tezacaftor/elexacaftor (cystic fibrosis, 2 to 5 years, F508del mutation, MF mutation, heterozygous) – Benefit assessment according to §35a Social Code Book | Commission completed |
Federal Joint Committee (G-BA)
2024-05-16 A G-BA decision was published.